Diabetic Retinopathy Market to Reach $10.11 Billion by 2022: Grand View Research, Inc.
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 07/23/15 -- Global is expected to reach USD 10.11 billion by 2022, according to a new study by Grand View Research Inc. Diabetic retinopathy is considered as a serious sight threatening complication that results due to long term diabetes. The treatment line selection for diabetic retinopathy depends on the severity of the condition and may require intraocular injections, anti VEGF drugs, laser surgery or vitrectomy. Increasing incidences of diabetes, rising geriatric population base and the growing demand for early detection are some high impact rendering drivers of the diabetic retinopathy market.
Furthermore, improving healthcare infrastructure, rising demand for cost-effective and safe treatment and rising focus of market players on emerging nations such as India and China are also anticipated to propel market growth. Presence of supportive government initiatives such as the Queen Elizabeth Diamond Jubilee Trust, which is taking initiatives for increasing patient awareness levels in order to promote regular retinal screening and early laser surgery to prevent permanent visual impairment and Ophthalmic Society of South Africa which works towards the improvement of reimbursement policies are anticipated to fuel the growth of the diabetic retinopathy market over the forecast period.
Anti VEGF is identified as the most attractive sub segment of the diabetic retinopathy market, growing at a rate of over 6.0% over the forecast period owing to, the rising incidences of diabetes and high efficacy rates
The non proliferative diabetic retinopathy segment accounted for the largest market share in 2014. The growing geriatric population and rising incidences of blindness caused due to diabetes are some key factors accounting for its large share. Furthermore, the increasing demand for regular retinal screening for long time diabetic patients is also expected to boost segment growth.
The North American diabetic retinopathy market accounted for over 35.0% of the revenue in 2014 on account of, the presence of high diagnostic and therapeutic rates in the U.S. The rising patient awareness levels and the presence of favorable government initiatives encouraging regular retinal screening is expected to drive regional market growth.
The Asia Pacific diabetic retinopathy market is likely to witness lucrative growth over the forecast period due to, the presence of unmet needs in the developing economies such as China and India. Presence of favorable government initiatives to enhance retinal screening rates and improving healthcare infrastructure are also expected to contribute towards rapid market growth.
Some key players of the diabetic retinopathy market include Bayer Healthcare, Novartis AG, ThromboGenics, Regeneron Pharmaceuticals Inc., Actavis Plc, Alimera Sciences, BCN Peptides and Kowa Group
Proliferative
Non proliferative
Anti VEGF
Intraocular steroid injection
Laser surgery
Vitrectomy
North America
U.S.
Canada
Europe
Germany
UK
Rest of Europe
Asia Pacific
Japan
China
Rest of Asia Pacific
Latin America
Brazil
Rest of Latin America
Middle East and Africa (MEA)
South Africa
Rest of Middle East and Africa
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email:
Web:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.07.2015 - 12:30 Uhr
Sprache: Deutsch
News-ID 408708
Anzahl Zeichen: 0
contact information:
Town:
SAN FRANCISCO, CA
Kategorie:
Alternative
Diese Pressemitteilung wurde bisher 234 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Diabetic Retinopathy Market to Reach $10.11 Billion by 2022: Grand View Research, Inc."
steht unter der journalistisch-redaktionellen Verantwortung von
Grand View Research, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
